Literature DB >> 27004693

Histopathological Outcomes after Irreversible Electroporation for Prostate Cancer: Results of an Ablate and Resect Study.

W van den Bos1, R R Jurhill2, D M de Bruin3, C D Savci-Heijink2, A W Postema4, P G K Wagstaff4, B G Muller4, I M Varkarakis5, A Skolarikos5, P J Zondervan4, M P Laguna Pes4, T M de Reijke4, J J M C H de la Rosette4.   

Abstract

PURPOSE: Irreversible electroporation is a tissue ablation modality that uses high voltage electric energy to induce an increase in cell membrane permeability. This causes destabilization of the existing cellular transmembrane potential leading to cell death, due to the inability to maintain cellular homeostasis. This phase I-II study was designed to evaluate the histopathological outcomes of irreversible electroporation to prostate and surrounding tissue in radical prostatectomy specimens.
MATERIALS AND METHODS: Sixteen patients with prostate cancer underwent an irreversible electroporation ablation without curative intent, followed by radical prostatectomy scheduled 4 weeks later. For histopathological examination of the prostate, whole mounted tissue slices were examined by dedicated genitourinary pathologists. The borders of the ablation zone and residual tumor were outlined on the slides.
RESULTS: The irreversible electroporation ablation zones were characterized as areas of fibrosis, necrosis and loss of epithelial tissue in terms of denudation in the glandular structures. The ablation zone was well demarcated, showing trenchant delineations between viable and nonviable tissue. The ablated tissue showed mild to moderate inflammation, with atrophic cells in 1 case. The area was surrounded by hemorrhage at the location of the electrodes. No skip lesions or viable tissue was seen in the ablation zone. Fibrinoid necrosis of the neurovascular bundle was observed in 13 patients and denudation of the urothelium of the prostatic urethra was seen in 9.
CONCLUSIONS: Histopathological assessment of the prostate 4 weeks after irreversible electroporation ablation showed sharply demarcated fibrotic and necrotic tissue in the ablation zone. No viable tissue was observed in the irreversible electroporation ablation zone.
Copyright © 2016 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ablation techniques; electroporation; pathology; prostatic neoplasms

Mesh:

Year:  2016        PMID: 27004693     DOI: 10.1016/j.juro.2016.02.2977

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  9 in total

1.  Impact on genitourinary function and quality of life following focal irreversible electroporation of different prostate segments.

Authors:  Matthijs J Scheltema; John I Chang; Willemien van den Bos; Ilan Gielchinsky; Tuan V Nguyen; Theo de M Reijke; Amila R Siriwardana; Maret Böhm; Jean J de la Rosette; Phillip D Stricker
Journal:  Diagn Interv Radiol       Date:  2018-09       Impact factor: 2.630

Review 2.  Irreversible Electroporation for the Ablation of Prostate Cancer.

Authors:  Andreas Karagiannis; John Varkarakis
Journal:  Curr Urol Rep       Date:  2019-09-02       Impact factor: 3.092

3.  Irreversible electroporation for the treatment of localized prostate cancer: a summary of imaging findings and treatment feedback.

Authors:  Matthijs J Scheltema; Arnoud W Postema; Daniel M de Bruin; Mara Buijs; Marc R Engelbrecht; M Pilar Laguna; Hessel Wijkstra; Theo M de Reijke; Jean J M C H de la Rosette
Journal:  Diagn Interv Radiol       Date:  2017 Sep-Oct       Impact factor: 2.630

Review 4.  Targeted Anterior Gland Focal Therapy-a Novel Treatment Option for a Better Defined Disease.

Authors:  Kae Jack Tay; Arnauld Villers; Thomas J Polascik
Journal:  Curr Urol Rep       Date:  2016-10       Impact factor: 3.092

Review 5.  "Super-active surveillance": MRI ultrasound fusion biopsy and ablation for less invasive management of prostate cancer.

Authors:  Jonathan B Bloom; Samuel A Gold; Graham R Hale; Kareem N Rayn; Vikram K Sabarwal; Ivane Bakhutashvili; Vladimir Valera; Baris Turkbey; Peter A Pinto; Bradford J Wood
Journal:  Gland Surg       Date:  2018-04

Review 6.  Irreversible Electroporation for Prostate Cancer as Salvage Treatment Following Prior Radiation and Cryotherapy.

Authors:  Katie S Murray; Oguz Akin; Jonathan A Coleman
Journal:  Rev Urol       Date:  2017

7.  Pair-matched patient-reported quality of life and early oncological control following focal irreversible electroporation versus robot-assisted radical prostatectomy.

Authors:  Matthijs J Scheltema; John I Chang; Maret Böhm; Willemien van den Bos; Alexandar Blazevski; Ilan Gielchinsky; Anton M F Kalsbeek; Pim J van Leeuwen; Tuan V Nguyen; Theo M de Reijke; Amila R Siriwardana; James E Thompson; Jean J de la Rosette; Phillip D Stricker
Journal:  World J Urol       Date:  2018-03-28       Impact factor: 4.226

8.  Prostate cancer treatment with Irreversible Electroporation (IRE): Safety, efficacy and clinical experience in 471 treatments.

Authors:  E Guenther; N Klein; S Zapf; S Weil; C Schlosser; B Rubinsky; M K Stehling
Journal:  PLoS One       Date:  2019-04-15       Impact factor: 3.240

9.  Numerical simulation modeling of the irreversible electroporation treatment zone for focal therapy of prostate cancer, correlation with whole-mount pathology and T2-weighted MRI sequences.

Authors:  Matthijs J Scheltema; Tim J O'Brien; Willemien van den Bos; Daniel M de Bruin; Rafael V Davalos; Cees W M van den Geld; Maria P Laguna; Robert E Neal; Ioannis M Varkarakis; Andreas Skolarikos; Phillip D Stricker; Theo M de Reijke; Christopher B Arena; Jean de la Rosette
Journal:  Ther Adv Urol       Date:  2019-06-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.